<DOC>
	<DOCNO>NCT00928512</DOCNO>
	<brief_summary>This study ass Week 16 efficacy safety AIN457 different dos patient active RA despite stable MTX therapy . Treatment continue Week 48 safety follow-up Week 60 ass long term efficacy safety AIN457 treatment combination MTX RA .</brief_summary>
	<brief_title>Efficacy , Safety Tolerability AIN457 Patients With Rheumatoid Arthritis ( RA ) Taking Methotrexate ( MTX )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Presence RA classify ACR 1987 revise criterion . Patients active RA MTX least 3 month must currently treat stable dose MTX ( &gt; =7.5 mg/week &lt; = 25 mg/week ) least 4 week At Baseline : Disease activity criterion define &gt; = 6 28 tender joint &gt; = 6 28 swollen joint WITH either Screening value hsCRP &gt; = 10 mg/L OR ESR &gt; = 28 mm/1st hr RA patient functional status class IV classify accord ACR 1991 revise criterion Patients take high potency opioid analgesic ( e.g. , methadone , hydromorphone , morphine ) Any therapy intraarticular injection ( e.g . corticosteroid ) require treatment acute RA flare within 4 week randomization Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Rheumatoid Arthritis , RA , ACR , inflammatory joint</keyword>
</DOC>